Tiziana Life Sciences Ltd (TLSA) - News Archive

The landscape of drug development for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) is fraught with challenges, yet it is also imbued with the potential for groundbreaking advancements. On March...

The Growing Commitment: Tiziana Life Sciences’ Chairman Boosts Stake Amid Promising Developments in Alzheimer s TreatmentIn a significant move reflective of confidence and support for Tiziana Life Sciences Ltd. (Nasdaq:...

Promising Developments in Alzheimer s Treatment: Tiziana Life Sciences Intranasal Foralumab Shows Significant Reduction in Microglia ActivationTiziana Life Sciences, a biotechnology company known for its innovative ther...

In a strategic move that underscores its commitment to innovation in the biopharmaceutical sector, Tiziana Life Sciences has announced a collaborative agreement with Renaissance Lakewood, LLC, a notable player in Contra...

Tiziana Life Sciences Signals Positive Forward Trajectory with Strategic Capital Decision in Immunotherapy DevelopmentOn January 23, 2025, Tiziana Life Sciences, Ltd. (Nasdaq: TLSA), a notable contender in the biotechno...

New York, Nov. 19, 2024 Tiziana Life Sciences, Ltd. (Nasdaq: TLSA), a pioneering biotechnology company focused on developing transformative immunomodulation therapies, announced a significant milestone in their journey...

On September 19, 2024, Tiziana Life Sciences, a biotechnology firm specializing in immunomodulation therapies, announced the receipt of a significant $4 million grant from the National Institutes of Health (NIH) to stud...

Tiziana Life Sciences: Innovative Breakthrough and Ongoing Financial Challenges Shape Its FutureIn an exciting breakthrough, Tiziana Life Sciences, a renowned biotechnology company, has been granted Fast Track designati...

Tiziana Life Sciences, a leading biotechnology company specializing in the development of breakthrough therapies for neurodegenerative diseases, has announced the receipt of non-dilutive funding amounting to $3.4 millio...

In recent news, Tiziana Life Sciences has achieved a significant milestone in its pursuit of developing innovative immunomodulation therapies for various diseases, particularly non-active, secondary-progressive multiple...

Multiple Sclerosis (MS) manifests as a neuroinflammatory and neurodegenerative disorder with significant patient morbidity. Secondary Progressive Multiple Sclerosis (SPMS) represents a stage of the disease characterized...

Tiziana Life Sciences Ltd, a biotechnology company renowned for developing groundbreaking immunomodulation therapies, has recently submitted a grant application to the ALS Association. The Company seeks to secure fundin...

Tiziana Life Sciences, a biotechnology company specializing in immunomodulation therapies, has filed for Orphan Drug Designation for intranasal foralumab in the treatment of non-active secondary progressive multiple scl...

Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal ForalumabNEW YORK, April 25, 2024 - Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (Tiziana or the Compa...

Therapeutic Potential of Foralumab in Treating Fatigue in Non-Active Secondary Progressive Multiple Sclerosis PatientsFatigue is a common symptom experienced by individuals with multiple sclerosis (MS), particularly tho...

Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system, leading to significant disability and impairment in millions of individuals worldwide. The need for more effective and wel...

Tiziana Life Sciences, a leading biotechnology company, has made significant strides in their research and development efforts by filing a new patent application for a novel combination therapy. The proposed therapy com...

Tiziana Life Sciences, a trailblazer in the development of potentially revolutionary neuro-immunomodulation treatments, has initiated dosing the first patient in its Phase 2a clinical trial exploring the effects of intr...

New York, November 30, 2023 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA), a leading biotechnology company focused on developing innovative immunomodulation therapies through novel drug delivery methods, announced today t...